CLINICAL STUDIES OF SIGNAL TRANSDUCTION INHIBITORS
CLINICAL STUDIES OF SIGNAL TRANSDUCTION INHIBITORS
批准号:
6173296
负责人:
ALEX A. ADJEI
金额:
$14.03万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-09-30 至 2002-09-29
中文摘要
描述:(申请人描述)
调节细胞信号转导在肿瘤细胞转化中起关键作用
扩散。新型抗癌药物在不同部位的阻断作用
细胞信号通路正在进入临床。雷帕霉素是一种新的
靶向单一蛋白mTOR的免疫抑制剂,它似乎
在以前未知的信号转导途径中所必需的功能
为G1/S期细胞周期转换。雷帕霉素具有抗增殖作用
在各种类型的肿瘤细胞中都有活性。
这项应用利用雷帕霉素及其类似物作为重点
在临床发育治疗学方面发展事业。申请人
建议:1.利用雷帕霉素类似物作为
抑制细胞内信号转导的抗癌药物研究进展
小路。A.具有生长抑制活性的雷帕霉素类似物将进入
不久将进行临床试验。在细胞中观察到了抗增殖作用
表达EGF和PDGF受体的类型。然而,初步研究表明,
表明决定肿瘤敏感性的关键生长因子
肿瘤细胞对雷帕霉素的类似物是IGF。在这些临床研究中,
肿瘤的敏感性依赖于EGF、PDGF和IGF的表达
在肿瘤组织样本(免疫组织化学)和患者血清中检测
(血清免疫分析)。B.靶蛋白mTOR及其其中一种的含量
肿瘤组织样本中可能的靶点p70K将通过
免疫印迹。结果将与肿瘤对
雷帕霉素。C.由于这些药剂主要是细胞抑制药,结合
最初将利用克隆形成试验对这些方案进行体外测试。这个
新型信号转导调节器mTOR是这些研究的目标
通过不依赖ras的途径刺激细胞增殖。因此,
联合研究的候选药物将包括(I)其他细胞
干扰ras途径的信号分子,如法尼化
抑制剂,以及(Ii)非环类的经典细胞毒剂
依赖于铂的类似物。2.提高临床专业知识
通过参加生物统计学课程进行药物开发研究,阶段
I临床试验设计,参与药物动力学/药物代谢
分析、科学会议(戈登会议、AACR特别会议、
EORTC-NCI新药研讨会)。
英文摘要
DESCRIPTION: (Applicant's Description)
Regulated cell signaling is critical in neoplastic cell transformation and
proliferation. Novel anticancer agents interrupting different points in
cell signaling pathways are entering the clinic. Rapamycin is a novel
immunosuppressive agent targeting a single protein mTOR, which appears to
function in a previously unrecognized signal transduction pathway necessary
for G1/S phase cell cycle transition. Rapamycin has anti-proliferative
activity in a variety of tumor cell types.
This application utilizes rapamycin and its analogues as a focus in
developing a career in clinical developmental therapeutics. The applicant
proposes to: 1. utilize the rapamycin analogues as a model for the
development of anticancer agents inhibiting intracellular signaling
pathways. a. Rapamycin analogues with growth inhibitory activity will enter
clinical trials shortly. Anti-proliferative effects have been seen in cell
types which express EGF and PDGF receptors. Preliminary studies, however,
indicate that the critical growth factor determining the sensitivity of
tumor cells to the rapamycin analogues is IGF. In these clinical studies,
the dependence of tumor sensitivity on EGF, PDGF, and IGF expression will be
tested in tumor tissue samples (immunohistochemistry) and patient serum
(serum immunoassay). b. Content of the target protein mTOR and one of its
putative targets p70K in tumor tissue samples will be assayed via
immunoblotting. Results will be correlated with tumor response to
rapamycin. c. Since these agents are predominantly cytostatic, combination
regimens will be tested initially in vitro utilizing clonogenic assays. The
novel signal transduction regulator mTOR, which is the target of these
agents, stimulates cell proliferation via a ras-independent pathway. Thus
candidate drugs for combination studies will include (I) other cell
signaling agents interfering with the ras pathway such as the farnesylation
inhibitors, and (ii) classical cytotoxic agents which are non-cycle
dependent such as the platinum analogues. 2. improve expertise in clinical
drug development research through attending courses in biostatistics, phase
I clinical trial design, involvement in pharmacokinetic/drug metabolism
analyses, scientific meetings (Gordon Conference, AACR special meetings,
EORTC-NCI new drug symposia).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors
-
批准号:9815079
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2018
-
负责人:ALEX A. ADJEI
-
依托单位:
Phase 2 Clinical Trials Program for Experimental Therapeutics Clinical Trials Network
-
批准号:9094959
-
项目类别:
-
资助金额:$91.25万
-
财政年份:2014
-
负责人:ALEX A. ADJEI
-
依托单位:
Network Lead Academic Participating Site Grant from the Roswell Cancer Inst.
-
批准号:8846079
-
项目类别:
-
资助金额:$52.36万
-
财政年份:2014
-
负责人:ALEX A. ADJEI
-
依托单位:
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
-
批准号:9086290
-
项目类别:
-
资助金额:$71.82万
-
财政年份:2014
-
负责人:ALEX A. ADJEI
-
依托单位:
Data & Safety Monitoring
-
批准号:7714444
-
项目类别:
-
资助金额:$5.14万
-
财政年份:2008
-
负责人:ALEX A. ADJEI
-
依托单位:
Protocol-Specific Research Support
-
批准号:7714441
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2008
-
负责人:ALEX A. ADJEI
-
依托单位:
Protocol Review & Monitoring
-
批准号:7714440
-
项目类别:
-
资助金额:$7.6万
-
财政年份:2008
-
负责人:ALEX A. ADJEI
-
依托单位:
Clinical Research Services
-
批准号:7714435
-
项目类别:
-
资助金额:$13.18万
-
财政年份:2008
-
负责人:ALEX A. ADJEI
-
依托单位:
Protocol Review and Monitoring System
-
批准号:7432964
-
项目类别:
-
资助金额:$5.58万
-
财政年份:2007
-
负责人:ALEX A. ADJEI
-
依托单位:
Protocol Specific Research
-
批准号:7432966
-
项目类别:
-
资助金额:$17.33万
-
财政年份:2007
-
负责人:ALEX A. ADJEI
-
依托单位:
Data and Safety Monitoring
-
批准号:7432961
-
项目类别:
-
资助金额:$13.83万
-
财政年份:2007
-
负责人:ALEX A. ADJEI
-
依托单位:
EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR ZD1839
-
批准号:7206214
-
项目类别:
-
资助金额:$1.23万
-
财政年份:2005
-
负责人:ALEX A. ADJEI
-
依托单位:
CORE-- Protocol-Specific Research Support
-
批准号:6989963
-
项目类别:
-
资助金额:$9.16万
-
财政年份:2004
-
负责人:ALEX A. ADJEI
-
依托单位:
Paclitaxel & Carboplatin in Combination with Farnesyl
-
批准号:7042288
-
项目类别:
-
资助金额:$0.56万
-
财政年份:2003
-
负责人:ALEX A. ADJEI
-
依托单位:
Phase I Study of Docetaxel/Irinotecan with Celecoxib
-
批准号:7042342
-
项目类别:
-
资助金额:$1.16万
-
财政年份:2003
-
负责人:ALEX A. ADJEI
-
依托单位:
CLINICAL STUDIES OF SIGNAL TRANSDUCTION INHIBITORS
-
批准号:6376647
-
项目类别:
-
资助金额:$14.53万
-
财政年份:1997
-
负责人:ALEX A. ADJEI
-
依托单位:
Experimental Therapeutics Program
-
批准号:10362645
-
项目类别:
-
资助金额:$9.84万
-
财政年份:1997
-
负责人:ALEX A. ADJEI
-
依托单位:
CLINICAL STUDIES OF SIGNAL TRANSDUCTION INHIBITORS
-
批准号:2796398
-
项目类别:
-
资助金额:$16.14万
-
财政年份:1997
-
负责人:ALEX A. ADJEI
-
依托单位:
CLINICAL STUDIES OF SIGNAL TRANSDUCTION INHIBITORS
-
批准号:2561015
-
项目类别:
-
资助金额:$10.22万
-
财政年份:1997
-
负责人:ALEX A. ADJEI
-
依托单位:
CLINICAL STUDIES OF SIGNAL TRANSDUCTION INHIBITORS
-
批准号:2896365
-
项目类别:
-
资助金额:$15.81万
-
财政年份:1997
-
负责人:ALEX A. ADJEI
-
依托单位:
海外基金